Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Amgen’s Humira Biosimilar Recommended for EMA Approval

XTALKS VITALS NEWS

Biosimilar

If the EMA takes the advice of the CHMP, Amjevita could be approved to treat a number of conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

Share this!

February 1, 2017 | by Sarah Hand, M.Sc.

An advisory committee to the European Medicines Agency (EMA) recently recommended the approval of Amgen’s biosimilar of AbbVie’s Humira. The drug was originally submitted for European approval back in late 2015, with the biosimilar – marketed as Amjevita – approved by the US Food and Drug Administration (FDA) in September of 2016.

If the EMA takes the advice of the CHMP, Amjevita could be approved to treat a number of conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. According to the committee, “studies have shown that Amgevita has comparable quality, safety and efficacy to Humira.”



In addition to Amjevita, the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended the approval of seven other drugs. The committee also announced that Sandoz had withdrawn its application for approval of its biosimilar of Amgen's Neulasta.

Neulasta is not Amgen’s top selling product, however biosimilar competition for the biologic could certainly have an effect on sales of the drug. As Novartis’ generic unit, Sandoz, has withdrawn their application for now, Amgen will have more time to plan for the potential launch of the copycat biologic in the future.

However, Novartis has plans to resubmit the Neulasta biosimilar to the EMA in late 2017. The drugmaker also plans to resubmit the drug for approval by the FDA in 2018.


Keywords: Biosimilar, Biologic, EMA


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.